It is prescription-only, offered after clinical assessment, and is distinct from Rybelsus, a lower-dose oral semaglutide licensed for type 2 diabetes
Lawsuits allege that Saxenda, like other GLP-1 receptor agonist drugs, has caused serious gastrointestinal injuries, severe vomiting, and increased risk of stomach paralysis
Diabetes Ther 14:21592172 Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I (2021) Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study
In terms of how it comparises to Ozempic, the researchers wrote in the paper: "Ecnoglutide, a novel GLP-1 receptor agonist, is composed entirely of natural amino acids with chemical modifications to enhance stability and activity, differing from semaglutide by four amino acids." They explained these modifications not only improve how the drug works but the manufacturing process in this case too